Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF MARIDEBART CAFRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY (MARITIME-CV)

Intervention/treatment:
MARIDEBART CAFRAGLUTIDE (AMG 133)
Medical condition:
OVERWEIGHT/OBESITY
Protocol code:
20220196
Control number:
298511
Status:
Recruiting
Approved:
June 26, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07037433
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
45 Years to 99 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Amgen Call Center
Role
CONTACT
Phone:
866-572-6436
Sponsor
AMGEN CANADA INC

Locations

Alberta

Janek Senaratne Professional Medical Corporation
Edmonton, Alberta, T6K 4C1
Recruiting

British Columbia

Discovery Clinical Services Ltd
Victoria, British Columbia, V8T 5G4
Recruiting
Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, V5Z 1M9
Recruiting

New Brunswick

G A Research Associates Limited
Moncton, New Brunswick, E1G 1A7
Recruiting

Ontario

Aggarwal and Associates Ltd
Brampton, Ontario, L6T 0G1
Recruiting
Cambridge Cardiac Care Centre
Cambridge, Ontario, N1R 6V6
Recruiting
Centricity Research Brampton
Brampton, Ontario, L6S 0C6
Recruiting
Diabetes Heart Research Centre
Toronto, Ontario, M6G 1M2
Recruiting
Heart Health Institute Research Incorporated
Scarborough Village, Ontario, M1B 4Z8
Recruiting
KMH Cardiology Centres Incorporated Hamilton
Stoney Creek, Ontario, L8J 3W2
Recruiting
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B 3H7
Recruiting

Quebec

Centre de Recherche du Centre Hospitalier de l Universite de Montreal
Montreal, Quebec, H2X 0C1
Recruiting
Centre intégré de santé et service sociaux de Lanaudière
Saint-Charles-Borromee, Quebec, J6E 6J2
Recruiting
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
Recruiting
Institut Universitaire de cardiologie et de pneumologie de Quebec
Quebec, Quebec, G1V 4G5
Recruiting
Montreal Heart Institute
Montreal, Quebec, H1T 1C8
Recruiting
Research Institute of McGill University Health Center - Glen Site
Montreal, Quebec, H4A 3J1
TERMINATED
Did you find what you were looking for?